Skip to main content
Clinical Trials/NCT02212548
NCT02212548CompletedNot Applicable

Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose

Royal North Shore Hospital1 site in 1 country30 target enrollmentStarted: March 1, 2012Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
Evaluation of serious adverse events or complications secondary to PEG hydrogel insertion.

Study Overview

Brief Summary

This is a Phase I prospective study of 30 patients to determine whether PEG hydrogel (SpaceOAR) reduces the dose of radiation delivered to the rectum during Image Guided Intensity Modulated Radiotherapy (IG-IMRT) for prostate cancer, by increasing the space between the prostate and the rectum.

Detailed Description

Patients who are referred to the Northern Sydney Cancer Centre for radiotherapy for treatment of their prostate cancer will be screened at the initial consultation for suitability for participation in the study. Following informed consent, those who agree to participate in the study will undergo the following procedures. Blood tests will be performed to ensure normal coagulation profile and renal function prior to any procedure. Under transrectal ultrasound guidance, patients will have insertion of fiducial gold seeds into the prostate under anaesthesia. While the patient is in theatre and under anaesthesia, the PEG hydrogel (SpaceOAR) will be inserted by Dr Thomas Eade, who will be competent in the procedure. The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time (comes with commercial product). The solutions will be injected within 30 minutes of mixing. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. This hydrodissection, prior to delivery of the hydrogel, should create a distance of 3-4 mm between the prostate and the rectum. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the hydrogel is injected in a smooth, continuous technique. The gel sets up within approximately 8 seconds.

In order to compare the effect of the PEG hydrogel (SpaceOAR) on the dose of radiation received by the rectum, two radiotherapy plans will be created. One planning CT scan will therefore be performed prior to the injection of the PEG hydrogel and one one week following injection of the hydrogel. The two treatment plans will be created by the same radiation therapist.

As the hydrogel is clearly visible on MRI and not on CT scans, we will obtain a pelvic MRI scan following injection of the hydrogel.. The MRI scans will be used in planning and fused to the planning CT scans to aid voluming.

Treatment:

Patients will undergo standard prostate cancer planning and treatment using image guided dose escalated IMRT as per the RNSH Department protocol and guidelines to a dose of 80Gy in 40 fractions 14.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Prostate cancer, confirmed with histopathology specimen;
  • •Eligible for prostate radiotherapy, either for definitive treatment or to aid local control in patients with known metastatic disease.

Exclusion Criteria

  • •Metastatic disease where local radiotherapy is not recommended management
  • •Complications following prostate biopsy including infection
  • •Urinary retention symptoms
  • •Bleeding disorder
  • •Renal impairment
  • •Anal fistula or perianal abscess

Arms & Interventions

Hydrogel

Experimental

The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the 'PEG Hydrogel (SpaceOAR) is injected in a smooth, continuous technique.

Intervention: PEG Hydrogel (SpaceOAR) (Device)

Outcomes

Primary Outcomes

Evaluation of serious adverse events or complications secondary to PEG hydrogel insertion.

Time Frame: Post-Hydrogel Insertion then 2nd weekly during radiation therapy up to 9 weeks and at a 3 month follow-up.

Physcian reported toxicity using CTC

% volume of rectum receiving 40Gy, 65Gy, 70Gy, 75Gy and 80Gy

Time Frame: CT scans taken 1-2 weeks apart (Pre and post Hydrogel insertion)

Estimated % volume of rectum as measured on CT dosimetry based on CT scans ore and post insertion of hydrogel taken 1-2 weeks apart (% volume of rectum receiving 40Gy, 65Gy, 70Gy, 75Gy and 80Gy).

Secondary Outcomes

  • Gastrointestinal toxicity(Second weekly evaluation during radiation therapy up to 9 weeks and at 3 mths, 9 mths, 15 mths, 21 mths, 27mths and 36mths post treatment.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Professor Thomas Eade

Dr.

Royal North Shore Hospital

Study Sites (1)

Loading locations...

Similar Trials